The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Therapeutic Targeting of Oncogenic K‐Ras by a Covalent Catalytic Site Inhibitor
Open accessAbstract
We report the synthesis of a GDP analogue, SML‐8‐73‐1, and a prodrug derivative, SML‐10‐70‐1, which are selective, direct‐acting covalent inhibitors of the K‐Ras G12C mutant relative to wild‐type Ras. Biochemical and biophysical measurements suggest that modification of K‐Ras with SML‐8‐73‐1 renders the protein in an inactive state. These first‐in‐class covalent K‐Ras inhibitors demonstrate that irreversible targeting of the K‐Ras guanine‐nucleotide binding site is potentially a viable therapeutic strategy for inhibition of Ras signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“SM-10-70-1 showed increased cellular permeability and competitively inhibited KRASG12C through covalent binding.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [91]
In the citing paper
“In addition, KRAS-dependent signaling pathways, such as the Akt and Erk pathways, are also inhibited.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [91]
In the citing paper
“Therefore, SM-10-70-1 (22) was synthesized by modifying phosphoric acid groups of SML-8-73-1 with “caging” technology.91”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [91]
In the citing paper
“Moreover, the ability of SM-10-70-1 to exhibit anti-proliferative activity was demonstrated in several cancer cell lines expressing the KRASG12C mutation.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [91]
In the citing paper
“was recently found to be targetable by small-molecule inhibitors (8, 9).”
In the citing paper
“SML-10-70-1, a GDP-derived analog that covalently modifies cysteine 12 of K-RasG12C, was identified with anti-proliferative activity in KRASG12C mutant models.53”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [53]
In the citing paper
“However, SML-10-70-1 functioned as a nonspecific K-RasG12C inhibitor, as K-RasG12S-bearing cells also responded to this compound.53”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [53]
In the citing paper
“Accordingly, inhibitors of this type are KRASG12C specific; therefore, they do not affect RAS signalling in non-malignant cells65,70–72 and, at least theoretically, have a low risk of on-target, off-tumour toxicities.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [72]
In the citing paper
“Lim et al. reported the synthesis of a GDP analog, SML-8-73-1, which contains an electrophilic chloroacetamide attached to the β-phosphate. This analog can covalently modify cysteine 12 of KRasG12C and, as a result, it competes with GTP and GDP for active site binding in a cellular context (38).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [38]
In the citing paper
“Earlier studies have identified small molecules selectively recognizing and irreversibly inactivating one specific KRAS-mutant allele harboring a G12C amino acid substitution (37, 38).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Barbacid, M. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.004023 · Cited by 3,885
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc969 · Cited by 3,354
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2559 · Cited by 2,648
Self-citationCOSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063
Mammalian Ras interacts directly with the serine/threonine kinase raf
Vojtek, A. B., Hollenberg, S. M., & Cooper, J. A. (1993) · Cell · doi:10.1016/0092-8674(93)90307-c · Cited by 1,934
The Guanine Nucleotide-Binding Switch in Three Dimensions
Vetter, I. R., & Wittinghofer, A. (2001) · Science · doi:10.1126/science.1062023 · Cited by 1,875
The Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants
Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., & Wittinghofer, A. (1997) · Science · doi:10.1126/science.277.5324.333 · Cited by 1,543
Milburn, M. V., Tong, L., deVos, A. M., Brünger, A. T., Yamaizumi, Z., Nishimura, S., & Kim, S. (1990) · Science · doi:10.1126/science.2406906 · Cited by 1,062
Flagged first, then by citations
Research works printed but not linked: 1
- Bos J. L., 1989, Cancer Res., 49, 4682
Cited by
Sorted by citations
Items 201–300 of 307
The Research Progress of Direct KRAS G12C Mutation Inhibitors
Yang, A., Li, M., & Fang, M. (2021) · Pathology and Oncology Research · doi:10.3389/pore.2021.631095 · Cited by 15
“In 2014, Lim et al [11] proposed the molecule SML-10-70-1 in a paper published in Angewandte Chemie; SML-10-70-1 was able to achieve a small decrease in pERK and pAkt at 100 μM and had no effect on wildtype KRAS.”
BackgroundAdvances and Challenges in RAS Signaling Targeted Therapy in Leukemia
Chen, Y., Yin, Z., Westover, K. D., Zhou, Z., & Shu, L. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0504 · Cited by 15
Self-citationLi, A., Li, S., Wang, P. G., Dang, C., Fan, X. M., Chen, M., Liu, D., Li, F., Liu, H., Zhang, W., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02939 · Cited by 15
Rationale for RAS Mutation-Tailored Therapies
Montalvo, S. K., Li, L., & Westover, K. D. (2016) · Future Oncology · doi:10.2217/fon-2016-0363 · Cited by 15
Self-citationCai, R., Huang, M., & Wang, Y. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.8b03727 · Cited by 15
NMR in integrated biophysical drug discovery for RAS: past, present, and future
Marshall, C. B., KleinJan, F., Gebregiworgis, T., Lee, K., Fang, Z., Eves, B. J., Liu, N. F., Gasmi-Seabrook, G. M. C., Enomoto, M., & Ikura, M. (2020) · Journal of Biomolecular NMR · doi:10.1007/s10858-020-00338-6 · Cited by 15
Targeting integrin-linked kinase to suppress oncogenic KRAS signaling in pancreatic cancer
Chu, P., Kulp, S. K., Bekaii‐Saab, T., & Chen, C. (2016) · Small GTPases · doi:10.1080/21541248.2016.1251383 · Cited by 15
Therapeutic Targeting the Allosteric Cysteinome of RAS and Kinase Families
Li, L., Meyer, C., Zhou, Z.-W., Elmezayen, A., & Westover, K. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167626 · Cited by 14
Self-citationGerber, D. E., Socinski, M. A., Neal, J. W., Wakelee, H. A., Shirai, K., Sequist, L. V. D., Rosovsky, R. P. G., Lilenbaum, R., Bastos, B. R., Huang, C. H., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.01.010 · Cited by 14
Pancreatic Tumorigenesis: Oncogenic KRAS and the Vulnerability of the Pancreas to Obesity
Luo, Y., Li, X., Ma, J., Abbruzzese, J. L., & Lu, W. (2021) · Cancers · doi:10.3390/cancers13040778 · Cited by 14
Modeling of RAS complexes supports roles in cancer for less studied partners
Engin, H. B., Carlin, D. E., Pratt, D. R., & Carter, H. K. (2017) · BMC Biophysics · doi:10.1186/s13628-017-0037-6 · Cited by 14
Defeat mutant KRAS with synthetic lethality
Pang, X., & Liu, M. (2016) · Small GTPases · doi:10.1080/21541248.2016.1213783 · Cited by 14
Shai, A., Galouk, E., Miari, R., Tareef, H., Sammar, M., Zeidan, M., Rayan, A., & Falah, M. (2022) · Oncology Letters · doi:10.3892/ol.2022.13250 · Cited by 15
Analysis of KRAS–Ligand Interaction Modes and Flexibilities Reveals the Binding Characteristics
Zhao, Z., Bohidar, N., & Bourne, P. E. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00097 · Cited by 13
Janero, D. R. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.925876 · Cited by 14
Mutant-Specific Targeting of Ras G12C Activity by Covalently Reacting Small Molecules
Goody, R. S., Müller, M. P., & Rauh, D. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.07.005 · Cited by 14
Ostrem, J. M. L., Peters, U., & Shokat, K. M. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01691-5 · Cited by 12
The complex journey of targeting RAS in oncology
Wasiak, K., Ciunowicz, D., Kierasińska, A., Węgierska, M., Pacholczyk, M., Rieske, P., & Stoczyńska-Fidelus, E. (2025) · BMC Cancer · doi:10.1186/s12885-025-14033-y · Cited by 14
GLOBAL AND TARGETED PROFILING OF GTP‐BINDING PROTEINS IN BIOLOGICAL SAMPLES BY MASS SPECTROMETRY
Huang, M., & Wang, Y. (2020) · Mass Spectrometry Reviews · doi:10.1002/mas.21637 · Cited by 12
SP3‐FAIMS‐Enabled High‐Throughput Quantitative Profiling of the Cysteinome
Desai, H. S., Yan, T., & Backus, K. M. (2022) · Current Protocols · doi:10.1002/cpz1.492 · Cited by 9
Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine
Aredo, J. V., & Padda, S. K. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0557-6 · Cited by 12
“Oh, Dear We Are in Tribble”: An Overview of the Oncogenic Functions of Tribbles 1
Singh, K., Showalter, C. A., Manring, H. R., Haque, S. J., & Chakravarti, A. (2024) · Cancers · doi:10.3390/cancers16101889 · Cited by 10
Wolfe, A. R., & Williams, T. M. (2018) · Annals of Pancreatic Cancer · doi:10.21037/apc.2018.08.02 · Cited by 10
How to make an undruggable enzyme druggable: lessons from ras proteins
Sayyed–Ahmad, A., & Gorfe, A. A. (2020) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2020.05.003 · Cited by 11
Luo, L., Zheng, T., Wang, Q., Liao, Y., Zheng, X., Zhong, A., Huang, Z., & Luo, H. (2022) · Pharmaceuticals · doi:10.3390/ph15050584 · Cited by 10
Direkte Modulation von Aktivität und Funktion kleiner GTPasen
Cromm, P. M., Spiegel, J., Grossmann, T. N., & Waldmann, H. (2015) · Angewandte Chemie · doi:10.1002/ange.201504357 · Cited by 9
Wang, Y., He, M., Li, X., Chai, J., Jiang, Q., Peng, C. Y., He, G., & Huang, W. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.700956 · Cited by 9
Martín‐Gago, P., Fansa, E. K., Klein, C. H., Murarka, S., Janning, P., Schürmann, M., Metz, M., Ismail, S., Schultz‐Fademrecht, C., Baumann, M., et al. (2017) · Angewandte Chemie · doi:10.1002/ange.201610957 · Cited by 8
Shrestha, G., MacNeil, S. M., McQuerry, J. A., Jenkins, D. F., Sharma, S., & Bild, A. H. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.06.012 · Cited by 10
A Guanidyl‐Based Bivalent Peptidomimetic Inhibits K‐Ras Prenylation and Association with c‐Raf
Tsubamoto, M., Le, T. K., Li, M., Watanabe, T., Matsumi, C., Parvatkar, P. T., Fujii, H., Kato, N., Sun, J., & Ohkanda, J. (2019) · Chemistry - A European Journal · doi:10.1002/chem.201903129 · Cited by 9
Development of a high-throughput TR-FRET screening assay for a fast-cycling KRAS mutant
Larson, J. E., Hardy, P. B., Schomburg, N. K., Wang, X., Kireev, D., Rossman, K. L., & Pearce, K. H. (2022) · SLAS DISCOVERY · doi:10.1016/j.slasd.2022.12.001 · Cited by 9
Targeting the “undruggable” RAS - new strategies - new hope?
Mörchen, B., Shkura, O., Stoll, R., & Helfrich, I. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.21 · Cited by 8
Molecular interaction between K-Ras and H-REV107 in the Ras signaling pathway
Han, C. W., Jeong, M. S., & Jang, S. B. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.07.120 · Cited by 7
RASpecting the oncogene: New pathways to therapeutic advances
Stout, M. C., & Campbell, P. M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.10.022 · Cited by 7
Inhibition of GTPase KRAS G12D : a review of patent literature
Li, Y., Yang, L., Li, X., & Zhang, X. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2369630 · Cited by 7
Lau, H. Y., & Wang, M. (2017) · Small GTPases · doi:10.1080/21541248.2017.1415637 · Cited by 7
Spiclomazine displays a preferential anti-tumor activity in mutant KRas-driven pancreatic cancer
Guo, X., Zhao, W., Liu, Z., & Wang, J. (2018) · Oncotarget · doi:10.18632/oncotarget.24025 · Cited by 7
Targeting the RAS-RAF-MEK-ERK Signaling Pathway in Gliomas
See, W. L., & Mukherjee, J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812100-9.00022-x · Cited by 7
Prajapati, V., Singh, A. K., Kumar, A. M., Singh, H., Pathak, P., Grishina, M., Kumar, V., Khalilullah, H., Verma, A., & Kumar, P. (2025) · RSC Medicinal Chemistry · doi:10.1039/d4md00923a · Cited by 6
Vargas-Ibarra, D., Velez-Vasquez, M., & Bermudez-Muñoz, M. (2021) · Post-Translational Modifications in Cellular Functions and Diseases [Working Title] · doi:10.5772/intechopen.97061 · Cited by 6
Moving Towards Dawn: KRas Signaling and Treatment in Pancreatic Ductal Adenocarcinoma
Bhattacharya, S., & Rajpurohit, T. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467215666220128161647 · Cited by 6
Targeting oncogenic KRasG13C with nucleotide-based covalent inhibitors
Goebel, L., Kirschner, T., Koska, S., Rai, A., Janning, P., Maffini, S., Vatheuer, H., Czodrowski, P., Goody, R. S., Müller, M. P., et al. (2023) · eLife · doi:10.7554/elife.82184 · Cited by 6
A noncanonical GTPase signaling mechanism controls exit from mitosis in budding yeast
Zhou, X., Weng, S. Y., Bell, S. P., & Amon, A. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2413873121 · Cited by 6
Selektive Inhibierung von mutiertem Ras‐Protein durch kovalent bindende Liganden
Rudolph, J., & Stokoe, D. (2014) · Angewandte Chemie · doi:10.1002/ange.201400233 · Cited by 6
Growth factor transduction pathways: paradigm of anti-neoplastic targeted therapy
Carlomagno, F., & Chiariello, M. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1177-7 · Cited by 6
Ras proteins as therapeutic targets
Chakraborty, A., Linnane, E., & Ross, S. J. (2018) · Biochemical Society Transactions · doi:10.1042/bst20170529 · Cited by 6
Li, R., Huang, X., Wang, R., Ren, Z., Zhu, Y. L., Lu, T., Sun, Y., & Hao, C. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117718 · Cited by 6
Hussain, J., Chhabria, D., & Kirubakaran, S. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127290 · Cited by 5
Evolution of structure-guided drug design strategies targeting mutations in codon 12 of KRAS
Dorandish, S., Bhayekar, K., Singh, A., Kushwaha, N. D., Malin, E., Serafimovski, S., Kelm, J. M., Gavande, N. S., & Lakkaniga, N. R. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00169b · Cited by 6
Mao, Y., Yao, H., Wang, H., Cheng, P., & Long, D. (2016) · Angewandte Chemie · doi:10.1002/ange.201608653 · Cited by 5
Targeting the Architecture of Deregulated Protein Complexes in Cancer
Stefan, E., Troppmair, J., & Bister, K. (2017) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2017.07.001 · Cited by 5
KRAS et adénocarcinome bronchique. Entre déceptions et espoirs
Guibert, N. M., Ilié, M., Léna, H., Didier, A. P., Hofman, P. M., & Mazières, J. (2015) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2015.05.012 · Cited by 4
Assays for Nucleotide Competitive Reversible and Irreversible Inhibitors of Ras GTPases
Jeganathan�, S., Müller, M. P., Ali, I., & Goody, R. S. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00234 · Cited by 6
KRAS: Structure, function, and development of anticancer drugs
Parasrampuria, D. A., Yu, A., & Haddish‐Berhane, N. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818168-3.00013-9 · Cited by 3
The Role of the Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in Cancer
Lotfaliansaremi, S., Sabio, M. L., Comwell, S., & Tolias, P. P. (2020) · Medical Research Archives · doi:10.18103/mra.v8i4.2086 · Cited by 3
Validation of Isoform- and Mutation-Specific RAS Antibodies
Waters, A. M., & Der, C. J. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1190-6_5 · Cited by 3
KRAS - An Evolving Cancer Target.
Ye, N., & Zhou, J. (2014) · PubMed · Cited by 3
The Endeavours in RAS Inhibition - the Past, Present, and Future
Hussain, J., Kirubakaran, S., & Ravi, S. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200903163044 · Cited by 3
Jiang, Y., Liu, X., Lv, D.-L., & Zhao, X.-L. (2021) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001176 · Cited by 3
Drugging the undruggable: Ross Cagan interviews Kevan Shokat
Cagan, R. L., & Shokat, K. M. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049468 · Cited by 3
Zhu, Y., Chen, Z., Wu, G., Fang, Y., Bao, Y., Zhu, J., Dong, G., Sheng, C., & He, S. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02636 · Cited by 2
Targeting KRASG13C with cyclic linker based inhibitors to explore warhead orientation
Kirschner, T., Rodriguez, J., Moreira, E. G., Niggenaber, J., Warmuth, J. D., Verli, H., Müller, M. P., & Rauh, D. (2025) · Scientific Reports · doi:10.1038/s41598-025-22145-5 · Cited by 2
Immediate and Selective Control of Protein Abundance Using the dTAG System
Nabet, B., & Gray, N. S. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160691-00055 · Cited by 2
Self-citationScreening Strategies for Drug Discovery and Target Identification
Al‐Awadhi, F. H., Salvador, L. A., & Luesch, H. (2015) · CRC Press eBooks · doi:10.1201/b19081-10 · Cited by 2
Smith, B. P., Rigby, M., Ma, R., & Maciag, A. E. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3822-4_20 · Cited by 2
Bifunctional Small Molecule Ligands of K-Ras Induce Its Association with Immunophilin ProteinsPreprint
Zhang, Z., & Shokat, K. M. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/619551 · Cited by 2
The future of covalent inhibition
Keserű, G. M., & Erlanson, D. A. (2020) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2020.10.003 · Cited by 1
Covalent inhibitors of K-Ras G12S, G12R, and G12D
Zhang, Z., & Shokat, K. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00024-3 · Cited by 1
Covalently targeting KRAS G12C
Janes, M. R., Li, L., Hansen, R., Peters, U., Ren, P., & Liu, Y. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00008-5 · Cited by 1
Novel paradigms in KRAS targeting: Unveiling strategies to combat drug resistance
Luo, X., Zhou, F., Tang, Y., Liu, X., Xiao, R., Gu, M., Bai, J., Jiang, D., Yang, G., You, L., et al. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003776 · Cited by 2
Davoudi, Z., Dexheimer, T. S., Coussens, N. P., Silvers, T. E., Fox, R. G., Kemp, S. B., Juneja, P., Morris, J., Hollingshead, M. G., Takebe, N., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0582 · Cited by 2
Dubiella, C., Baur, R., Cui, H., Huber, E. M., & Groll, M. (2015) · Angewandte Chemie · doi:10.1002/ange.201506631 · Cited by 1
GTP-Competitive Inhibitors of RAS Family Members
Hunter, J. C., Gray, N. S., & Westover, K. D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803505-4.00009-6 · Cited by 1
Self-citationSearch for Inhibitors of Ras-Driven Cancers
Keeton, A. B., & Piazza, G. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803505-4.00008-4 · Cited by 1
Targeting der kleinen GTPasen über ihre regulatorischen Proteine
Gray, J. L., von Delft, F., & Brennan, P. E. (2019) · Angewandte Chemie · doi:10.1002/ange.201900585 · Cited by 1
Oncogenic G12D mutation alters local conformations and dynamics of K-RasPreprint
Vatansever, S., Erman, B., & Gumus, Z. H. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/178483 · Cited by 1
Editorial: Signaling by Small GTPases in Metastatic Disease
Parker, P. J., & Kishore, U. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.841572 · Cited by 1
Davoudi, Z., Dexheimer, T. S., Coussens, N. P., Silvers, T. E., Morris, J., Takebe, N., Doroshow, J. H., & Teicher, B. A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.17.623998 · Cited by 1
Social Interactomes for Enabling Research Communities
Guinney, J., Dienstmann, R., Ferté, C., Friend, S. H., & McCormick, F. P. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0774
Yang, W. (2016) · Illinois Digital Environment for Access to Learning and Scholarship (University of Illinois at Urbana-Champaign)
Foulkes, D. M., Byrne, D. P., Bailey, F. P., Ferries, S., Eyers, C. E., Keeshan, K., Shrestha, S., Yeung, W., Kannan, N., Wells, C. I., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/305243
Regulation of the kRAS Promoter in Pancreatic Cancer by Proteins and Small Molecules
Batra, H. (2017) · ProQuest Demo Repository
Development of split luciferase complementation probes sensing KRAS/effector interaction
Miyamoto, K., Ishihara, K., & Sawa, M. (2019) · Translational and Regulatory Sciences · doi:10.33611/trs.1_40
Gao, Q., Ouyang, W., Kang, B., Han, X., Xiong, Y., Ding, R., Li, Y., Wang, F., Huang, L., Chen, L., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/807578
Ras and Ras Signaling as a Therapeutic Target in Cancer
Sliker, B. H., & Campbell, P. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00006-2
Chemical Approach Toward Controlling of Transient Protein Interactions
Ohkanda, J. (2021) · Springer eBooks · doi:10.1007/978-981-16-2458-2_5
Applications of Constrained Helices
Li, Z., Zhao, H., & Wan, C. (2021) · Wiley eBooks · doi:10.1002/9783527343430.ch4
Deredge, D. J., & Wintrode, P. L. (2017) · Structure · doi:10.1016/j.str.2017.08.012
Evaluation of K-Ras4B dimer interfaces and the role of Raf effectorsPreprint
Chatzigoulas, A., Andreadelis, I., Doerr, S., Lamprakis, C., Theodoropoulou, A., Manchester, J. I., Velez‐Vega, C., Duca, J. S., & Cournia, Z. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.04.510804
Additional file 2 of Inhibition of ERAD synergizes with FTS to eradicate pancreatic cancer cells
Du, R., Sullivan, D. K., Azizian, N. G., Liu, Y., & Li, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14175865
First molecules to reactivate RASG12V GTPase activity
Włodarczyk, A., Tręda, C., Pacholczyk, M., Rutkowska, A., Węgierska, M., Kierasińska, A., Wasiak, K., Ciunowicz, D., Grot, D., Głowacki, P., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-13580-8
Targeting RAS and associated proteins
Müller, M. P., Goody, R. S., & Rauh, D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00008-x
Additional file 1 of Inhibition of ERAD synergizes with FTS to eradicate pancreatic cancer cells
Du, R., Sullivan, D. K., Azizian, N. G., Liu, Y., & Li, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14175862
Targeting the RAS/RAF/MEK/ERK signaling pathway in gliomas
Gao, Y., Grant, M. G. M., Liu, J. K. C., & Wan, L. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27356-8.00025-5
Identification of therapeutic targets of nucleolin-related pathways in pancreatic cancer therapy
Raineri, F. (2020) · theses.fr (ABES) · doi:10.70675/b0a30a01z777cz4da7z90cbz3e9a95dd1630
Rôle de c-Jun dans la réponse aux inhibiteurs de la voie des MAPK dans les mélanomes
Pohorecka, M. (2018) · theses.fr (ABES) · doi:10.70675/4cf7db7bz9142z4de8zbcbbzd5860991d571
BindingDB (2026) · UC San Diego · doi:10.7270/q26w9gxr
Metadata
- Authors
- Lim, S. M., Westover, K. D., Ficarro, S. B., Harrison, R. A., Choi, H. G., Pacold, M. E., Carrasco, M., Hunter, J., Kim, N. D., Xie, T., Sim, T., Jänne, P. A., Meyerson, M., Marto, J. A., Engen, J. R., & Gray, N. S.
- Affiliations
- Harvard University (US)
- The University of Texas Southwestern Medical Center (US)
- Dana-Farber Cancer Institute (US)
- Northeastern University (US)
- Daegu-Gyeongbuk Medical Innovation Foundation (KR)
- Korea Institute of Science and Technology (KR)
- Broad Institute (US)
- Corresponding author
- Gray, Nathanael S.
- ORCID
- Venue
- Angewandte Chemie International Edition
- Publisher
- Wiley
- Published
- 2013-11-20
- Volume
- 53
- Issue
- 1
- Pages
- 199-204
- ISSN
- 1433-7851 (ISSN-L)
- 1521-3773
- PMC
- PMC3914205
- OpenAlex
- W2141965353
- Cited by
- 300
- References
- 30
- Citations by year
- 2026: 4 · 2025: 13 · 2024: 15 · 2023: 10 · 2022: 18 · 2021: 21 · 2020: 31 · 2019: 34 · 2018: 27 · 2017: 36 · 2016: 37 · 2015: 29 · 2014: 24
- FWCI
- 13.60
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Angewandte Chemie International Edition (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA130876)
- National Institute of General Medical Sciences (R01GM101135, GM101135)
- National Institute of Neurological Disorders and Stroke (P01NS047572)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- covalent inhibitors, prodrugs, Ras signaling inhibition, oncogenic Ras, small molecule inhibitors
- MeSH terms
- Drug Design, Signal Transduction, ras Proteins, Catalytic Domain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
